Education
About Us
Working with TipRanks
Follow Us
Guardant Health (GH)
NASDAQ:GH
GH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$18.01 - $52.92
Previous CloseN/A
Volume639.07K
Average Volume (3M)2.10M
Market Cap
$5.80B
Enterprise Value$5.88B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Jul 31, 2025EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding123,888,050
10 Day Avg. Volume2,723,834
30 Day Avg. Volume2,102,838
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-14.79
Forecast
1Y Price Target
$59.79Price Target Upside50.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
---
Bulls Say, Bears Say
Bulls Say
Market PositionGuardant Health maintains a leading position in the liquid biopsy market, making it an attractive investment.
Product PerformanceGuardant remains the best-in-class liquid biopsy opportunity, with its market-leading G360 assay in late stage cancer testing to its rapidly growing Shield CRC screening assay.
Revenue GrowthGuardant Health announced positive results, with total revenues significantly surpassing expectations.
Bears Say
Data ReliabilityThe data from Guardant's study should be taken with caution given the potential for degradation in a larger prospective study.
Regulatory ChallengesCommon issues cited as barriers to adoption of MCED tests included high cost, lack of Medicare coverage, insufficient non-Medicare coverage, and lack of FDA approval.
---
Ownership Overview
4.09% Insiders
26.75% Mutual Funds
0.05% Other Institutional Investors
51.24% Public Companies and
Individual Investors
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $18.01 and its highest was $52.92 in the past 12 months.
What is Guardant Health’s market cap?
Guardant Health’s market cap is $5.80B.
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Jul 31, 2025 which is in 83 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on Apr 30, 2025. The company reported -$0.77 earnings per share for the quarter, missing the consensus estimate of -$0.76 by -$0.01.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -0.72.
How many shares outstanding does Guardant Health have?
Guardant Health has 123,888,050 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$0.77 in its last earnings report, missing expectations of -$0.76. Following the earnings report the stock price went up 3.472%.
Which hedge fund is a major shareholder of Guardant Health?
Currently, no hedge funds are holding shares in GH
---
Guardant Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.79 (50.45% Upside)
$59.79 (50.45% Upside)
Blogger Sentiment
Bullish
GH Sentiment 87%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 112.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $165.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
119.52%
12-Months-Change
Fundamentals
Return on Equity
-4584.47%
Trailing 12-Months
Asset Growth
-21.14%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
---
GH Company Deck
---
GH Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment with strong revenue growth across multiple segments, gross margin improvements, and raised full-year guidance. However, challenges such as high cash burn and limited commercial payer reimbursement for Shield were noted.Read More>---
GH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
---
GH Stock 12 Month Forecast
Average Price Target
$59.79
▲(50.45% Upside)
Technical Analysis
---